🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06763835
Active, not recruiting Observational

Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis

NCT06763835 · tracked via the Priya Life Science China tracker
Sponsor
Xuebo Liu
Phase
Observational
Started
2023-02-01
Last updated
2025-01-14

Condition(s) studied

Plaque RuptureAcute Coronary Syndromes

Investigational drug(s) / intervention(s)

Blood is drawn to test for specific biomarkers

Blood is drawn to test for specific biomarkers: After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Study summary

The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is

• Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: people presenting with an acute coronary syndrome (ACS)-either non-ST-segment elevation myocardial infarction (NSTE-ACS); or ST-segment elevation myocardial infarction (STE-ACS), and subsequently underwent emergent coronary angiography followed by percutaneous coronary intervention (PCI). Culprit leisions were tested using optical coheren tomograpgy and pathological diagnosis(PE OR PR) were validated by 2 independent experienced core lab members. Exclusion Criteria: * patients younger than 18 years or older than 85 years * patients in cardiogenic shock * prior coronary artery bypass grafting, * patients with corornary stent thrombosis * patients with left main coronary disease * patients with congestive heart failure * patients with life-threatening arrhythmia * patients with thrombocytopenia patients with significant hepatic or renal impairment * patients with septicemia, leukopenia, active inflammatory or malignant disease * other factors compromising high-quality optical coherence tomography (OCT) imaging (e.g., severe vessel tortuosity or calcification, persistent no-reflow, lesions in distal segments, or an indeterminate culprit lesion) * Individuals unable to provide informed consent were also excluded.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital, Tongj University School of Medicine, 200333, Shanghai ,China Shanghai China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06763835 on ClinicalTrials.gov ↗ ← All trials in China